Effect of the urotensin receptor antagonist palosuran in hypertensive patients with type 2 diabetic nephropathy

Liffert Vogt, Carlos Chiurchiu, Harbajan Chadha-Boreham, Parisa Danaietash, Jasper Dingemanse, Samy Hadjadj, Henry Krum, Gerjan Navis, Eric Neuhart, Aneliya I. Parvanova, Piero Ruggenenti, Arend Jan Woittiez, Reuven Zimlichman, Giuseppe Remuzzi, Dick De Zeeuw

Research output: Contribution to journalArticlepeer-review

Abstract

The urotensin system has been hypothesized to play an important role in the pathophysiology of diabetic nephropathy. In this multicenter, randomized, double-blind, placebo-controlled, 2-period crossover study, the effects of the urotensin receptor antagonist palosuran on urinary albumin excretion and blood pressure in hypertensive patients with type 2 diabetic nephropathy treated with a single blocker of the renin-angiotensin-aldosterone system were assessed. Patients with 24-hour albuminuria >0.5 and 135 and 85 and

Original languageEnglish
Pages (from-to)1206-1209
Number of pages4
JournalHypertension
Volume55
Issue number5
DOIs
Publication statusPublished - May 2010

Keywords

  • Albuminuria
  • Diabetic nephropathy
  • Hypertension
  • Palosuran
  • RAAS blockade
  • Urotensin antagonist

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint Dive into the research topics of 'Effect of the urotensin receptor antagonist palosuran in hypertensive patients with type 2 diabetic nephropathy'. Together they form a unique fingerprint.

Cite this